A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Abroad (travel likely)RecruitingPHASE1
Conditions
Multiple Myeloma · Relapse Multiple Myeloma · Refractory Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Contact: Principal Investigator (David Avigan, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (David Avigan, MD)
Study leads
David Avigan, MD
Principal Investigator
Beth Israel Deaconess Medical Center